Table 1 Baseline characteristics of the study patients.

From: A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Baseline characteristics

N, median (%) [range] (N=16)

Age (years)

70 [20–30]

Gender

Female

11 (69)

Diagnosis

R/R AML

14 (88)

ND secondary AML

2 (12)

BM blasts (%)

36 [8–94]

Cytogenetics

Core Binding Factor [t (8;21)]

1 (6)

Diploid karyotype

4 (25)

Adverse karyotype

6 (38)

‐ Complex

4 (25)

Miscellaneous

5 (31)

ELN 2017 risk category

Favorable risk

1 (6)

Intermediate risk

5 (31)

Adverse risk

10 (63)

Mutations

ASXL1

4 (25)

DNMT3A

3 (18)

TET2

4 (25)

RUNX1

5 (31)

NRAS/KRAS

7 (44)

PTPN11

3 (18)

WT1

2(12)

Prior lines of therapy

 

3 [1–6]

Prior venetoclax

13 (93)

Prior allo-SCT

6 (38)

  1. N number, R/R relapsed refractory, ND newly diagnosed, ELN European LeukemiaNet, allo-SCT allogeneic stem cell transplantation.
Back to article page